Wayne L. Russell

Cost of acid peptic disorders in a managed-care organization

The purpose of this study was to determine the cost of managing ambulatory patients with symptoms of acid peptic disorders in a managed-care organization under actual clinical conditions. Study data were collected in a large independent practice association model health maintenance organization in Gainesville, Florida, from prescription records maintained in a computerized database and from patient medical records. Patients had to be started on a histamine2-receptor antagonist (H2RA) or the proton pump inhibitor omeprazole between 1992 and 1994. A total of 113 patients qualified for inclusion in the study; 57 received H2RAs, 27 received omeprazole, and 29 received combination therapy. The costs of procedures, physician visits, and drug therapy were considered in the economic evaluation. Costs were evaluated using two methods: the capitation total cost (CTC) and the fee-for-service total cost (FSTC). The mean CTC and FSTC for managing a patient with acid peptic symptoms for 6 months were

Dose-dependent kinetics of theophylline in adults with pulmonary diseases.

382 +/- 356 (range,

Effect of antacids on predicted steady-state cimetidine concentrations

14 to

Effect of concomitant antacid administration on plasma cimetidine concentrations during repetitive dosing.

1820) and

Amoxapine overdose: case report and pharmacokinetic profile.

456 +/- 368 (range,

Comparison of the predictions of one- and two-compartment microcomputer programs for long-term tobramycin therapy

52 to

Inadequacy of FDA Dosing Guidelines for Intravenous Theophylline

1925), respectively. Drug costs represented 52% of the total FSTC and 62% of the total CTC. Drug costs were followed by the costs for encounters with primary care physicians, endoscopy, referral to specialists, and upper gastrointestinal (UGI) tract procedures. Documented outcomes were available for 85 patients. Compared with patients receiving H2RAs (n = 41), patients receiving omeprazole (n = 18) had significantly lower FSTCs (

Lack of Clinically Significant In Vitro and In Vivo Interactions between Ranitidine and Sucralfate

317 +/- 219 compared with

Risk for Adverse Events among Patients Receiving Intravenous Histamine2-Receptor Antagonists

423 +/- 307, respectively); diagnostic testing costs (for endoscopy,

Use of i.v. cimetidine, ranitidine, and famotidine in 40 hospitals

0 compared with